In the same vein, alectinib activity in pretreated RET+ advanced NSCLC patients was assessed in two case series by Lin et al. (four patients) and by Ribeiro et al. (four patients), reporting one PR and one SD, one SD and one PMR (partial molecular response), respectively [49,50]. The gene discussed is RET; the disease is non-small cell lung carcinoma.